It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Platinum-based agents, such as cisplatin, form the mainstay of currently used chemotherapeutic regimens for several malignancies; however, the main limitations are chemoresistance and ototoxic side effects. In this study we used two different polyphenols, curcumin and ferulic acid as adjuvant chemotherapeutics evaluating (1) in vivo their antioxidant effects in protecting against cisplatin ototoxicity and (2) in vitro the transcription factors involved in tumor progression and cisplatin resistance. We reported that both polyphenols show antioxidant and oto-protective activity in the cochlea by up-regulating Nrf-2/HO-1 pathway and downregulating p53 phosphorylation. However, only curcumin is able to influence inflammatory pathways counteracting NF-κB activation. In human cancer cells, curcumin converts the anti-oxidant effect into a pro-oxidant and anti-inflammatory one. Curcumin exerts permissive and chemosensitive properties by targeting the cisplatin chemoresistant factors Nrf-2, NF-κB and STAT-3 phosphorylation. Ferulic acid shows a biphasic response: it is pro-oxidant at lower concentrations and anti-oxidant at higher concentrations promoting chemoresistance. Thus, polyphenols, mainly curcumin, targeting ROS-modulated pathways may be a promising tool for cancer therapy. Thanks to their biphasic activity of antioxidant in normal cells undergoing stressful conditions and pro-oxidant in cancer cells, these polyphenols probably engage an interplay among the key factors Nrf-2, NF-κB, STAT-3 and p53.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Neuroscience, Università Cattolica del Sacro Cuore, Roma, Italia (GRID:grid.8142.f) (ISNI:0000 0001 0941 3192); Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia (GRID:grid.414603.4)
2 Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia (GRID:grid.414603.4); Department of Head and Neck Surgery, Università Cattolica del Sacro Cuore, Roma, Italia (GRID:grid.8142.f) (ISNI:0000 0001 0941 3192)
3 Department of Neuroscience, Università Cattolica del Sacro Cuore, Roma, Italia (GRID:grid.8142.f) (ISNI:0000 0001 0941 3192)
4 Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia (GRID:grid.414603.4)
5 Department of Head and Neck Surgery, Università Cattolica del Sacro Cuore, Roma, Italia (GRID:grid.8142.f) (ISNI:0000 0001 0941 3192)